From your first consultation through your ongoing treatment, we prioritize your concerns, questions, and goals
Sanjeev Sockalingam, Scientific Director, framed the approval as a regulatory milestone that should "prompt governments, insurers, and employers to reconsider how obesity treatment is covered within these systems," noting that "fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications" [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]
Ceriello A, Novials A, Canivell S, La SL, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S
QDs and fluorescent semiconducting polymer dots (Pdots) also showed attractive attention as theranostic agents